Table 4 Univariate analysis of overall survival in all 171 patients (log-rank test)
n | 1-year* | 3-year | 5-year | 10-year | p-value† | |
|---|---|---|---|---|---|---|
Age (in years) | 0.03† | |||||
≤53 | 88 | 88.6 (76) | 74.2 (57) | 68.8 (42) | 54.1 (10) | |
> 53 | 83 | 88 (73) | 62.8 (45) | 51.7 (26) | 42.8 (4) | |
Sex | 0.31 | |||||
Female | 71 | 85.9 (60) | 73.8 (45) | 64.6 (31) | 51.8 (9) | |
Male | 100 | 90 (89) | 65 (57) | 57.7 (37) | 44.4 (5) | |
Race | 0.20 | |||||
Caucasian | 140 | 88.6 (124) | 66.4 (81) | 59.1 (55) | 44.4 (11) | |
non-Caucasian | 31 | 87.1 (25) | 79.8 (21) | 68.4 (13) | 68.4 (3) | |
PTT | 0.02† | |||||
Carcinoma | 87 | 93.1 (79) | 74.8 (58) | 69.2 (41) | 57.3 (7) | |
Sarcoma | 84 | 83.3 (70) | 62.5 (44) | 51.4 (27) | 39.2 (7) | |
DFI-1 | 0.79 | |||||
< 1 years | 34 | 76.5 (26) | 61.1 (16) | 57.3 (14) | 52.9 (2) | |
1 to 5 years | 92 | 90.2 (81) | 70.3 (5)4 | 60.3 (34) | 50 (7) | |
> 5 years | 45 | 93.3 (42) | 71.1 (32) | 63.5 (20) | 44.5 (5) | |
Laterality | 0.40 | |||||
Unilateral | 124 | 91.1 (112) | 72.4 (76) | 63.3 (49) | 46.4 (7) | |
Bilateral | 47 | 80.9 (37) | 58.8 (26) | 53.5 (19) | 49 (7) | |
Magnitude | 0.17 | |||||
Wedge | 118 | 88.1 (102) | 70 (71) | 63.8 (56) | 51.9 (12) | |
All other | 53 | 88.7 (47) | 65.8 (31) | 53.7 (12) | 36.9 (2) | |
Number of lesions | 0.64 | |||||
Single | 48 | 91.7 (44) | 71.8 (31) | 66.9 (24) | 47.8 (2) | |
2–5 | 94 | 89.4 (82) | 68 (53) | 58.5 (32) | 44 (6) | |
> 5 | 29 | 79.3 (23) | 65.5 (18) | 56.4 (12) | 56.4 (6) | |
Neoadjuvant | 0.10 | |||||
No | 99 | 85.9 (84) | 62.9 (55) | 54.4 (36) | 46.4 (7) | |
Yes | 72 | 91.7 (65) | 76.6 (47) | 69.3 (32) | 51.3 (7) | |
Procedure | 0.24 | |||||
OPEN | 135 | 87.4 (117) | 67.9 (88) | 58.8 (61) | 45.8 (14) | |
VATS | 36 | 91.7 (32) | 69.6 (14) | 69.6 (7) | 69.6 (0) |